Market closedNon-fractional
Enanta/ENTA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Enanta
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
Ticker
ENTA
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Watertown, United States
Employees
145
Website
www.enanta.com
Enanta Metrics
BasicAdvanced
$325M
Market cap
-
P/E ratio
-$6.25
EPS
0.54
Beta
-
Dividend rate
Price and volume
Market cap
$325M
Beta
0.54
Financial strength
Current ratio
6.428
Quick ratio
6.228
Long term debt to equity
115.951
Total debt to equity
138.377
Interest coverage (TTM)
-12.14%
Management effectiveness
Return on assets (TTM)
-22.87%
Return on equity (TTM)
-60.50%
Valuation
Price to revenue (TTM)
4.437
Price to book
1.97
Price to tangible book (TTM)
1.97
Price to free cash flow (TTM)
-2.854
Growth
Revenue change (TTM)
-10.22%
Earnings per share change (TTM)
4.22%
3-year revenue growth (CAGR)
-8.18%
3-year earnings per share growth (CAGR)
19.25%
What the Analysts think about Enanta
Analyst Ratings
Majority rating from 8 analysts.
Enanta Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q2 24
QoQ growth
Revenue
$17M
-5.56%
Net income
-$31M
-6.89%
Profit margin
-182.94%
-1.41%
Enanta Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q3 23
Q4 23
Q1 24
Q2 24
Q3 24
Actual
-$1.86
-$1.33
-$1.58
-$1.47
-
Expected
-$2.34
-$2.15
-$1.19
-$1.33
-$1.44
Surprise
-20.43%
-38.04%
32.33%
10.31%
-
Enanta News
AllArticlesVideos
Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference
Business Wire·2 months ago
Enanta Pharmaceuticals, Inc. (ENTA) Q2 2024 Earnings Call Transcript
Seeking Alpha·3 months ago
Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Enanta stock?
Enanta (ENTA) has a market cap of $325M as of July 27, 2024.
What is the P/E ratio for Enanta stock?
The price to earnings (P/E) ratio for Enanta (ENTA) stock is 0 as of July 27, 2024.
Does Enanta stock pay dividends?
No, Enanta (ENTA) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Enanta dividend payment date?
Enanta (ENTA) stock does not pay dividends to its shareholders.
What is the beta indicator for Enanta?
Enanta (ENTA) has a beta rating of 0.54. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Enanta stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.